Harbin Zhenbao Pharmaceutical Co., Ltd.

Novaonco Js Therapeutics Co., Ltd.

Other

Merck Sharp + Dohme Corp.

Medshine Discovery Inc.

Cgenetech (Suzhou, China) Co., Ltd.

Yaopharma Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

Wuxi Life Fountain Biotech Co., Ltd

Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.

Guangdong Xianqiang Pharmaceutical Co., Ltd

Shenzhen Lingfang Biotech Co., Ltd.

Cgenetech Co., Ltd.

Meibi Dai

Zhengxia Chen

Shuhui Chen

Jian Li

Yang Zhang

Guoping Hu

Xiaoxin Chen

Chaofeng Long

Zhuowei Liu

Yikai Wang

Deheng Sun

Wenju Li

Yuanfeng Xia

Jian Zuo

Xing Liu

William K Hagmann

Ravi P Nargund

Peng Li

Wei Wang

Hubert B Josien

Qun Dang

Bin Hu

Barbara A Pio

Jie Li

Fei Sun

Purakkattle J Biju

Bowei Wang

Linus S Lin

Bing Li

Harry R Chobanian

Timothy A Blizzard

Zhiqiang Liu

Zhen Gong

Cheng Xie

Timothy Allen Blizzard

Jason W Szewczyk

Dann Parker

Guibai Liang

Mingxiang Cui

Candido Gude

Jiangpeng Liao

Haixia Zhao

Zhoufan Xie

Yingxia Bao

Jiansong Wang

Zhibo Luo

Ying Lv

Hongfei Cheng

Suqin Yang

Zaihong Zhang

Lili Tian

The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Fluorovinylbenzamide compound as PD-L1 immunomodulator

FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.

Pyridine derivative as FGFR and VEGFR dual inhibitors

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

Pyrazolopyridine compound as RET inhibitor and application thereof

Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Vinylpyridine carboxamide compound as PD-L1 immunomodulator

A crystal form of an azaindole derivative and a preparation method thereof are disclosed.

Crystal form of azaindole derivative and use thereof

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof. 

Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor. 

Quinoline derivative and use thereof as tyrosine kinase inhibitor

Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof. 

Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases. 

FGFR4 inhibitor and preparation method and use thereof

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Vinyl compounds as FGFR and VEGFR inhibitors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

Growing community of inventors

Shanghai, China

Meibi Dai